CRJDM (CRJDM) Token Page

The core purpose of JDM-IPT is to accelerate diagnostic and therapeutic discovery in Juvenile Dermatomyositis by transforming parent-collected, at-home blood samples into ethically governed, high-resolution immune datasets powered by O’Ryan Health’s Artemis Platform and coordinated through an Intellectual Property Token (IPT) model. We have an IRB-approved study, and parents have successfully collected over 130 samples from their children in the JDM study.

JDM-IPT funding will empower families to continue collecting blood samples at home for rare disease research, building the first decentralized immune atlas for Juvenile Dermatomyositis, and accelerating discovery of early diagnostics and new treatments.Writing project descriptions can be tough, so here's a template to help you get started. Feel free to fill it out or delete it and write your own.